This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pharma Clinical Trial Services: World Market 2013-2023

NEW YORK, March 4, 2013 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Pharma Clinical Trial Services: World Market 2013-2023

Report Details

Discover new trends, opportunities and prospects for contract clinical trials

What's the outlook for clinical research providers? Visiongain's updated report gives you forecasted revenues to 2023. It explains trends, opportunities and commercial prospects.

Our study lets you assess sales data at overall world market, submarket and national level. There you find the most promising and lucrative areas in clinical trial outsourcing, helping your research and analyses.

Forecasts and other analyses to help you stay ahead in knowledge

In our work you find revenue forecasting to 2023, historical data, growth rates and market shares. Also, you see qualitative analysis (SWOT and STEP), business news, outlooks and developmental trends (R&D). You receive 74 tables, 61 charts and two survey interviews.

There's rising demand for that pharma research. The outsourced clinical trials market will increase its revenues from 2013 to 2023, achieving strong growth. Clinical research organisations (CROs) and their clients will benefit.

The following sections show what you find in our new report.

Discover prospects for the world market and submarkets

Along with revenue prediction for the overall world market, you see forecasts to 2023 for eight submarkets:• Early phase clinical trial services• Late phase services.

We also show forecasts for contract services by therapeutic area:

• Cancers

• Central nervous system (CNS) diseases

• Cardiovascular diseases

• Infections

• Metabolic disorders

• Other therapy areas (grouped prediction).

You gain advantages by understanding trends, opportunities and challenges. Our investigation shows what will stimulate and restrain business for CROs.

Our work also breaks the main world forecast into geographical markets.

1 of 13

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,831.70 +19.51 0.11%
S&P 500 2,090.83 +1.69 0.08%
NASDAQ 5,113.3180 +10.51 0.21%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs